Clinical Trial Update: Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy [Phase 1]

View source ↗

Summary

Phase I pharmacokinetic study of paclitaxel (Taxol) given as a 3-hour infusion in pediatric patients with refractory malignancies; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Taxol (paclitaxel)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neoplasms | Phase 1 | Status: COMPLETED